AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Insidehealthpolicy

Published November 12, 2026

HHS Taps Cuban To Build Ibogaine Supply, Prep US Trials For PTSD

Read the full story at Insidehealthpolicy

HHS plans to commit up to $4.9 million to lay the groundwork for U.S. trials of ibogaine as a potential treatment for post-traumatic stress.

Post on X

Share this story

Surfaced by this Google Alert

Ibogaine